Online inquiry

IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12231MR)

This product GTTS-WQ12231MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12231MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14031MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ15138MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SYNT-001
GTTS-WQ535MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 4D11
GTTS-WQ15699MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ2798MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ12602MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ4109MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI-204
GTTS-WQ11873MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW